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Abstract
Background: Specific cellular cytotoxic immune responses (CTL) are important in combating viral diseases and a highly
desirable feature in the development of targeted HIV vaccines. Adjuvants are key components in vaccines and may assist
the HIV immunogens in inducing the desired CTL responses. In search for appropriate adjuvants for CD8
+ T cells it is
important to measure the necessary immunological features e.g. functional cell killing/lysis in addition to immunological
markers that can be monitored by simple immunological laboratory methods.
Methodology/Principal Findings: We tested the ability of a novel two component adjuvant, CAF01, consisting of the
immune stimulating synthetic glycolipid TDB (Trehalose-Dibehenate) incorporated into cationic DDA (Dimethyldioctade-
cylammonium bromide) liposomes to induce CD8
+ T-cell restricted cellular immune responses towards subdominant
minimal HLA-A0201-restricted CTL epitopes from HIV-1 proteins in HLA-A*0201 transgenic HHD mice. CAF01 has an
acceptable safety profile and is used in preclinical development of vaccines against HIV-1, malaria and tuberculosis.
Conclusions/Significance: We found that CAF01 induced cellular immune responses against HIV-1 minimal CTL epitopes in
HLA-A*0201 transgenic mice to levels comparable with that of incomplete Freund’s adjuvant.
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Introduction
Generation of cellular immune responses are of high signifi-
cance in development of HIV-1 vaccines since the breath and
expansion of cytotoxic T-lymphocytes (CTL) is associated with
virus control [1,2,3]. To meet the high HIV-1 variation it is
preferred for a vaccine to include several antigens or epitopes.
After selection of vaccine epitope peptides, it is important to find
an appropriate adjuvant capable of inducing a strong cellular
immune response. In this search it is important to look for the
necessary immunological features e.g. cell killing/lysis and not just
immunological markers that can be monitored by simple
immunological laboratory methods. Not many adjuvants are
accessible for human use, and those, which can be used in
laboratory animal experiments, are often incompatible with
clinical trials in humans.
CAF01 is a novel adjuvant which has an acceptable safety
profile and proved successful in preclinical development of
antibody and Th cell activating vaccines against malaria and
tuberculosis and are currently in clinical trials [4,5]. Moreover,
CAF01 induces very robust memory T cell responses that are
maintained at high levels for .1 year postimmunization using a
tuberculosis subunit vaccine [6]. CAF01 consists of DDA and
TDB. DDA is a synthetic amphiphilic lipid compound comprising
a hydrophilic positively charged dimethylammonium head–group
attached to two hydrophobic 18-carbon alkyl chains (tail). In an
aqueous environment, DDA self-assemble into closed vesicular
bilayers (liposomes). The adjuvant efficacy and stability of the
liposomes (DDA) is increased by incorporation of the synthetic
glycolipid TDB (trehalose 6,69-dibehenate) which is a synthetic
analogue to the immune stimulatory component of the mycobac-
terial cell wall often referred to as the cord factor or
trehalosedimycolate [5,7,8].
To induce additional CTL immunity during chronic HIV-1
infection by a therapeutic vaccination we have identified
infrequently targeted but conserved HLA-A0201-restricted
epitopes from Gag, Pol, Env, Vpu and Vif [9,10,11]. These
relatively immune silent subdominant epitopes were modified
as anchor-optimized peptides to improve immunogenicity
for a vaccine. During development of our CTL inducing
therapeutic HIV-1 vaccine in HLA-A*0201 transgenic mice,
we have used the powerful standard incomplete Freund’s
adjuvant (IFA) which has, however, limited usability in
humans [9,10].
Here we show that CAF01 induced also functional CD8
+ T cell
immune responses against HIV-1 minimal CTL epitopes in HLA-
A*0201 transgenic mice to levels comparable with or better than
that of IFA.
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Novel adjuvant CAF01 helps inducing CTL similar to
incomplete Freund’s adjuvant
We compared the ability of the novel adjuvant CAF01 to induce
T-cell responses in HLA-A*0201 transgenic HHD mice [12] using
IFN-c ELISPOT and
51Cr-release cytolytic assay after subcuta-
neous (s.c.) immunization with a subdominant 9-mer epitope
Vif101 (GLADQLIHL) [10] together with the CD4
+ T-helper
epitope, PADRE [13]. The novel adjuvant CAF01 was compared
with incomplete Freund’s adjuvants (IFA).
We found that both the HLA-A2-restricted CD8 T-cell epitope
Vif101 and the CD4 Th epitope PADRE induced high responses
in IFN-c ELISPOT in both the IFA and CAF01 groups
(Figure 1A+B). After 5 days of in vitro peptide prestimulation of
splenocytes significant responses to Vif101 stimulation and PADRE
stimulation (Figure 1A+B). The Vif101 or the PADRE responses
were not significantly different between the IFA and CAF01
groups (t-test, p.0.05).
Splenocytes stimulated 5 days in vitro with Vif101 or the PADRE
peptide were analyzed for the ability to lyse peptide-loaded HHD
HLA-A*0201 target cells in a
51Cr-release cytolytic assay
(Figure 1C+D). We found that in the groups of animals adjuvanted
with IFA only one mouse significantly lysed Vif101-loaded target
cells (Figure 1C), whereas three out of five mice adjuvanted with
CAF01 significantly lysed Vif101 loaded target cells (Figure 1D).
The CTL responses correlated with the ELISPOT responses in
the sense that the highest responses in the IFN-c ELISPOT were
those which gave also responses in the
51Cr-release cytolytic assay
(data not shown). Thus, CAF01 adjuvants supportetd CD8 T cell
responses as good as or better than IFA.
Including CD4
+ T-helper epitope increases CTL responses
In order to evaluate the effect of including a CD4
+ T-helper
epitope (PADRE) with the CAF01 adjuvants for the induction of a
CD8
+ T cell response towards a minimal subdominant CD8
+ T cell
epitope (Vif101) we immunized HLA-A*0201 transgenic HHD mice
subcutaneously(s.c.) withVif101with orwithout PADRE.Thenovel
adjuvant CAF01 wasused inboth immunizations. IFN-c ELISPOT
and a
51Cr-release cytolytic assay was used to evaluate the T cell
responses after five days in vitro stimulation.
We found that when immunizing with the CD8 T cell epitope
Vif101 together with PADRE Th epitope a high IFN-c (above
1000 SFU/million cells) towards Vif101 was seen in four out of five
animals (Figure 2A) whereas when immunizing with Vif101 alone a
similar response were seen in three out of five animals (Figure 2B).
Using
51Cr-release cytolytic assay (Figure 2C+D), we found that
in the animals immunized with Vif101 together with PADRE two
Figure 1. Cellular immune responses are induced to a similar level after immunization with IFA and CAF01. IFN-c ELISPOT responses
against (A) HLA-A2-restricted CD8 T cell epitope Vif101 and (B) PADRE Th epitope of splenocytes from HLA-A*0201 transgenic HHD mice after 10 days
of s.c. immunization with Vif101 and PADRE in either IFA (grey bars, n=5) or CAF01 adjuvants (black bars, n=5) and 5 days in vitro prestimulation with
individual epitopes. The background of an unimmunized mouse is substracted. Specific
51Cr-release from target cells preloaded with Vif101 after
incubation with effector splenocytes from Vif101 and PADRE immunized mice adjuvanted with (C) IFA (grey, n=5) or (D) CAF01 (black, n=5). The
percentage of specific lysis was calculated as 1006(experimental release-spontaneous release)/(total release-spontaneous release). Background lysis
from an unimmunized mouse is shown (open circles). Significant positive levels are considered for .10% lysis at a 50:1 ratio of effector:target (E:T)
cells. One representative experiment out of three. SFU, spot forming units.
doi:10.1371/journal.pone.0006950.g001
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whereas one out of five mice immunized with Vif101 alone lysed
Vif101-loaded target cells (Figure 1D).
Thus, CD8 T cell responses could be induced by the CTL
epitope peptides using the CAF01 adjuvants but including a CD4
T helper epitope improved the CTL response.
Immunization with novel adjuvant CAF01 induces
multiple CD8
+ T cell responses with proliferative capacity
Proliferative capacity is another desirable property of vaccine-
induced T cell responses. We therefore evaluated CD8
+ and CD4
+
T cell proliferation using CFSE labeling and 5 days in vitro
stimulation with individual peptides. Here we used multiepitope
immunization with a mixture of 7 HIV-1 derived HLA-A2-
restricted CTL epitopes (Gag150, Gag433, Env67, Pol606, Vpu66,
Vif101 and Vif23), plus two HIV-1 specific CD4
+ T-helper epitopes
(Gag298 and Env570) and one universal CD4
+ T-helper epitope
(PADRE).
We were able to detect also proliferative CD8
+ T cells
against the CD4
+ T-helper epitope PADRE in 10 out of 10
immunized mice (Figure 3A+B). In addition up to three minimal
CTL epitopes (Gag150,G a g 433,V i f 101)i n d u c e dC D 8
+ Tc e l l
proliferation in the CAF01 group and up to two epitopes
(Gag150,G a g 433) in the IFA group. Moreover PADRE induced
CD4
+ T cell proliferation in 10 out of 10 immunized mice (data
not shown).
Discussion
The new lipophillic adjuvant CAF01 has been found to assist in
generation antibody and CD4
+ T helper responses [5]. Here we
show that CAF01 also generate functional CD8
+ T-lymphocyte
responses towards HIV-1 derived minimal CTL epitope peptides
in HLA-A*0201 transgenic mice.
Immunological features of induced T cell responses were
evaluated using three different assays: IFNc ELISPOT,
51Cr-
release cytolytic assay and proliferation using CFSE labeling. The
51Cr-release cytolytic assay is recognized as a true functional
immunological activity assay where effector splenocytes from the
immunized animal are allowed to interact and lyse target cells
preloaded with the peptide of interest. Also proliferative capacity is
a wanted feature of vaccine induced CD8
+ T cell-responses. Using
all three assays we were able to detect CAF01 induced cellular
immune responses to levels comparable with or better than that of
incomplete Freund’s adjuvant. The level of CD8
+ T cell responses
in the ELISPOT assay can not directly be compared to the level of
CD4
+ T cell responses, as this mouse model contains a very low
level of CD8
+ T cells compared to CD4
+ T cells [12].
Not many adjuvants are accessible for human use, and those,
which can be used in laboratory animal experiments, are often
incompatible with clinical trials in humans. CAF01 is a novel
adjuvant which has an acceptable safety profile and proved
successful in preclinical development of human vaccines against
malaria and tuberculosis and are currently in clinical trials [4,5].
Figure 2. Cellular immune responses induced after immunization in CAF01 with or without a T helper epitope. IFN-c ELISPOT
responses against (A) Vif101 CTL epitope and (B) PADRE Th epitope of splenocytes from HLA-A*0201 transgenic HHD mice after 10 days of s.c.
immunization with Vif101 and PADRE (grey bars, n=5) or with Vif101 alone (black bars, n=5) and 5 days in vitro prestimulation with individual
epitopes. The background of an unimmunized mouse is substracted. Specific
51Cr-release from target cells preloaded with Vif101 after incubation with
effector splenocytes from individual mice immunized with (C) Vif101 and PADRE (grey, n=5) or (D) with Vif101 alone (black, n=5). The percentage of
specific lysis was calculated as 1006(experimental release-spontaneous release)/(total release-spontaneous release). Background lysis from an
unimmunized mouse is shown (open circles). Significant levels are considered .10% lysis at a 50:1 ratio of effector:target (E:T) cells. One
representative experiment out of three. SFU, spot forming units.
doi:10.1371/journal.pone.0006950.g002
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responses in HLA-A*0201 transgenic mice using CAF01 important.
In addition using multiepitope immunization with CAF01 we
were able to induce up to four different specific CD8
+ T cell
proliferative responses in one individual mouse. The most
frequently targeted epitopes were the relative dominant CTL
epitopes Gag150 (T2L), Gag433 and the Th epitope PADRE. This
dominance pattern was also seen using immunization with
dentritic cells as adjuvants pulsed with the same epitopes (data
not shown). The fact that the Th epitope PADRE induce CD4
+ as
well as CD8
+ T cell responses is explained by the fact that this
13-mer, contains also a minimal HLA-A*0201 binding epitope.
We also wanted to evaluate if including a CD4
+ T cell epitope
helped the induction of CTL responses in immunizations using
CAF01. Our data show a slight increase of CTL responses when
co-immunizing with PADRE. Even though the help from PADRE
in this limited set of data might not be convincing, it appears as the
trend is that PADRE provides help to CD8
+ T cells, and at least it
does not diminish CTL responses but add CD4
+ T cell response.
The adjuvantic properties of CAF01 for CD8
+ T-cell in humans
is planned to be tested in a therapeutic HIV-1 phase 1 trial using
minimal CD8
+ CTL and CD4
+ T cell epitope peptides, and may
prove CAF01 as a very attractive adjuvant component in future
therapeutic and prophylactic vaccine trials.
Materials and Methods
Ethics statement
Animal experiments were approved and done according to the
Danish Animal Experimentation Act, based on the Council of
Europe Convention ETS 123, on a license granted by the Ministry
of Justice.
HLA-A*0201 transgenic mice
The HHD transgenic mice kindly provided by F.A. Lemonnier,
Institut Pasteur, Paris, France, express a transgenic monochain
histocompatibility class I molecule in which the C-terminus of the
human b2-microglobulin (b2m) is covalently linked to the N-
terminus of a chimeric heavy chain (HLA-A2.1 a1-a2, H-2D
b a3-
transmembrane and intracytoplasmic domains) [12]. HHD mice
are homozygous for the transgene, and H-2D
b2/2 and b2m
2/2
double knock out, respectively.
Peptides
Epitope peptides identified as relevant for HIV-1 vaccination
[9,10,11] were synthesized by Schafer-N, Copenhagen, Denmark.
The purity of the peptides was .95%. The CTL epitope petides
used in the present study were: Vif101(M9L) (GLADQLIHL),
Gag150(T2L) (RLLNAWVKV), Gag433 (FLGKIWPS), Env67(V2I)
(NIWATHAC), Pol606(T9V) (KLGKAGYVV), Vpu66(A9V) (AL-
VEMGHHV), and Vif23(I9V) (SLVKHHMYV). As T-helper
epitopes we used a Gag298 (KRWIILGLNKIVRMY) [14],
Env570 (VWGIKQLQARVLAVERYLKD) [15], and the univer-
sal PADRE (aKXVAAWTLKAAa, X=cyclohexyl alanine,
a=D-alanine) [13].
HLA-A*0201 transgenic mice immunization
Animal experiments were approved and performed in accor-
dance with the legal requirements in Denmark. 6–7 weeks old
HLA-A*0201 transgenic mice were injected subcutaneously with
100 mg of the HLA-A2-restricted minimal epitope Vif101 peptide
plus 120 mg of the synthetic T-helper peptide PADRE or for
multiepitope immunizations 20 mg of each of the 10 peptides.
Peptides were adjuvanted either by incomplete Freund’s adjuvant
(IFA) or 250 mg DDA: 50 mg TDB (CAF01). At day 10 after
immunization, mice were sacrificed and the splenocytes were
recovered and used for CFSE proliferation assay, or re-stimulated
in vitro with the immunization-peptide, as previously described [9].
After 5 days, the cells were used for cytolytic
51Cr-release assay
and IFN-c ELISpot assay.
IFN-c enzyme-linked immunospot (ELISPOT) assay
A standard IFN-c ELISPOT assay was used as previously
described [9]. Splenocytes harvested at day 5 of re-stimulation were
used in duplicates with a titration of cells ranging from 500,000 to
18,000. Restimulation was done with 10 mg of antigen/mL during
18 hours of incubation at 37uC, 5% CO2. ConA (10 mg/ml) was
included as positive control. Numbers of specific IFNc-secreting
cells were measured in an ELISPOT reader (Autoimmun
Diagnostika GmbH, Strassberg, Germany), analyzed with AiD3.1
S.R software and expressed as numbers of spot-forming units (sfu)
per 10
6 input cells. The cut-off for positivity was 10 sfu (subtracted
the negative background of an unimmunized mouse) per 10
6
Figure 3. Proliferative CD8
+ T cell responses induced after
immunization with IFA and CAF01. The percentage of proliferating
CD3+CD8
+ splenocytes (having reduced CFSE dye) derived from HLA-
A*0201 transgenic HHD mice 10 days after s.c. immunization with a
peptide mix consisting of 10 peptides adjuvanted with (A) IFA or (B)
CAF01. The background proliferation of non-stimulated (NS) cells,
incubated with media alone is shown. The epitope peptides were (from
left to right): NS, Gag150, Gag433, Env67, Pol606, Vpu66, Vif101, Vif23, Gag298
(Th), Env570 (Th) and PADRE (Th).
doi:10.1371/journal.pone.0006950.g003
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mean background activity of ,5 sfu/10
6 input cells (spontaneous
release) [9].
Cytotoxic T Lymphocyte assay
A standard cytotoxic
51Cr-release assay was used as previously
described [9]. Briefly, HHD-EL4S3
-Rob target cells [12] were
mixed with peptide loaded splenocyte effector cells at effector:tar-
get cell ratios (E:T) of 100:1, 50:1, 25:1 and 12.5:1 in either
triplicates or 6-replicates.
51Cr-release was measured using a
microplate scintillation counter (Topcount, NXT, Packard,
Boston, USA). Spontaneous and total
51Cr-release was measured
by adding culture medium or a detergent (Triton X-100) 2% v/v,
respectively. The percentage of specific lysis was calculated as
1006(experimental release - spontaneous release)/(total release -
spontaneous release). Spontaneous and total release was in the
range of 1200 and 9000 counts per minutes, respectively.
CFSE proliferation assay
For measuring specific proliferation of mouse splenocytes we
used a standard CFSE proliferation assay in which splenocytes
were labeled with CFSE (5 mM) and stimulated with target peptide
(20 mg/ml) and cultured in vitro for 6 days before labeling with
anti-CD3-APC (BD Biosciences), anti-CD4-PE (BD Biosciences)
and anti-CD8-PerCP (BD Biosciences). PHA (10 mg/ml) was
included as positive control and media alone as negative control.
Data were acquired on a BD LSRII instrument using FACSdiva
software (BD Biosciences) and analyzed with FlowJo software
(TreeStar). The percentage of proliferating cells (having reduced
CFSE dye) was analyzed within CD3
+CD4
+ or CD3
+CD8+
lymphocytes.
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